UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000022594
Receipt number R000026041
Scientific Title The study of systemic influence by chemotherapy in elderly patients with lung cancer
Date of disclosure of the study information 2016/06/05
Last modified on 2016/06/03 13:29:42

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The study of systemic influence by chemotherapy in elderly patients with lung cancer

Acronym

The study of systemic influence by chemotherapy in elderly patients with lung cancer

Scientific Title

The study of systemic influence by chemotherapy in elderly patients with lung cancer

Scientific Title:Acronym

The study of systemic influence by chemotherapy in elderly patients with lung cancer

Region

Japan


Condition

Condition

lung cancer

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

To investigate the systemic influence by chemotherapy

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The comparison of the lung, heart, liver,and renal functions before and after chemotherapy

Key secondary outcomes

The assessment of quality of life


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. lung cancer patients
2. stage IIIB or IV
3. the patients who recieve chemotherapy in our hospital.
4. adequate organ functions
5. obtained written informed consent

Key exclusion criteria

1. significant severe diseases
2. active infection
3. symptomatic brain metastases
4. mental or psychological disorder
5. history of severe allergic reaction to any medication
6. in pregnancy
7. patients who judged to be inappropriate by the attending doctor

Target sample size

80


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Tatsuo Kimura

Organization

Osaka City University

Division name

Premier Preventive Medicine

Zip code


Address

ABENO HARUKAS 21F, 1-1-43, Abenosuji, abeno-ku, Osaka 545-6090 JAPAN

TEL

06-6624-4041

Email

kimutats@med.osaka-cu.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Tatsuo Kimura

Organization

Osaka City University

Division name

Premier Preventive Medicine

Zip code


Address

ABENO HARUKAS 21F, 1-1-43, Abenosuji, abeno-ku, Osaka 545-6090 JAPAN

TEL

06-6624-4041

Homepage URL

http://medcity21.jp/clinic/clinicalresearch.shtml

Email

kimutats@med.osaka-cu.ac.jp


Sponsor or person

Institute

Premier Preventive Medicine, Graduate School of Medicine, Osaka City University

Institute

Department

Personal name



Funding Source

Organization

Grant-in-Aid for Scientific Research(S)or(C), Japan Society for the Promotion of Science(JSPS)

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 06 Month 05 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2016 Year 05 Month 30 Day

Date of IRB


Anticipated trial start date

2016 Year 07 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

patient accrural period:
from July 2016 to March 2022


Management information

Registered date

2016 Year 06 Month 03 Day

Last modified on

2016 Year 06 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026041


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name